Abstract:
Fractional exhaled nitric oxide (FeNO) has emerged as a critical, non-invasive biomarker for the assessment of airway inflammation, particularly eosinophilic inflammation. Its measurement plays a pivotal role in the diagnosis, phenotyping, and management of various respiratory conditions. This article discusses the established importance of FeNO testing in clinical practice and highlights the specific advantages offered by the UBREATH BA200 FeNO analyzer in enabling efficient and reliable point-of-care testing.
The Critical Role of FeNO in Respiratory Disease Management
Airway inflammation is a central pathological feature in many respiratory diseases. Traditional assessment often relies on symptoms and lung function tests, which may not directly reflect the underlying inflammatory state. FeNO measurement fills this gap by providing an objective, immediate indicator of type 2 (T2) or eosinophilic airway inflammation.
Diagnosis and Phenotyping of Asthma: FeNO is a well-validated tool to support the diagnosis of asthma, especially allergic/eosinophilic asthma. Elevated FeNO levels help differentiate asthma from other causes of chronic cough and wheeze. It is instrumental in identifying patients with a T2-high phenotype who are more likely to respond to inhaled corticosteroids (ICS) and biologic therapies.
Guidance of Treatment and Monitoring Adherence: For patients diagnosed with asthma, serial FeNO measurements are recommended by international guidelines (e.g., GINA) to guide ICS therapy. A rising FeNO can signal worsening inflammation or poor adherence, prompting timely intervention, while a decreasing FeNO confirms therapeutic response. This allows for personalized treatment titration.
Applications in Other Respiratory Conditions: FeNO's utility extends beyond asthma. It aids in the evaluation and management of chronic cough, allergic rhinitis, and is being studied in chronic obstructive pulmonary disease (COPD) to identify the eosinophilic overlap phenotype for targeted steroid use. It also helps in predicting exacerbations and assessing uncontrolled inflammation.
In summary, FeNO testing enhances precision medicine in pulmonology by moving beyond symptom-based management to inflammation-guided care, leading to improved patient outcomes and optimized use of medications.
Advantages of the UBREATH BA200 FeNO Analyzer
The UBREATH BA200 is a state-of-the-art, handheld FeNO analyzer designed to translate the clinical value of FeNO testing into convenient, point-of-care reality. Its key advantages include:
High Precision & Compliance with Standards: The BA200 utilizes advanced electrochemical sensor technology and sophisticated algorithms to deliver highly accurate and reproducible results that align with the stringent American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines for FeNO measurement.
Exceptional Portability and Ease of Use: Its compact, lightweight, and handheld design allows for effortless use in diverse clinical settings—from hospital pulmonology departments and allergy clinics to general practice offices and even home visits. The intuitive user interface with clear visual and audio prompts makes operation simple for both healthcare professionals and patients.
Rapid, Hygienic Testing: The device provides results in under 30 seconds, facilitating immediate clinical decision-making during the consultation. The use of single-patient, disposable breathing guides ensures complete hygiene and eliminates the risk of cross-contamination. Internal check of electronics every time at start-up and last abnormal value. Auto-calibration technology support a compensation of flow, temperature, humidity,and atmospheric pressure
Cost-Effectiveness and Workflow Efficiency: By bringing the test to the patient's side, the BA200 eliminates the need for dedicated lab space and complex logistics. It streamlines the clinical workflow, increases patient throughput, and reduces overall management costs while providing invaluable diagnostic information.
Conclusion
FeNO measurement is an indispensable component of modern respiratory disease management, offering a direct window into airway inflammation for diagnosis, phenotyping, and treatment optimization. The UBREATH BA200 analyzer effectively harnesses this potential by combining clinical-grade accuracy with outstanding portability, hygiene, and smart features. It empowers clinicians at the point of care to make informed, timely, and personalized management decisions, ultimately advancing the standard of care for patients with asthma and other inflammatory respiratory conditions.
Post time: Dec-19-2025